Hycamtin

Uterine Cervical Neoplasms

National Cancer Institute (NCI)Phase 1/2Dormant

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 81/ 100

Competitive context

26 Active assets in the Uterine Cervical Neoplasms cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II Merck Sharp & Dohme LLC	Phase 3	BB
Pembrolizumab GV20 Therapeutics	Phase 3	BB
Carboplatin Eli Lilly and Company	Phase 2	B
FULVESTRANT Atavistik Bio, Inc	Phase 2	B
Capecitabine Merck Sharp & Dohme LLC	Phase 2	B

View all 29 →

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant

BBB

Indicative ·

74 / 100

cancer of unknown primary siteDormant

BBB

Indicative ·

72 / 100

non-small cell lung carcinomaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.